Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

By M. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. Chia, Charles M. Perou, Torsten O. Nielsen. Clinical Cancer Research, 2008

1,210 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/d06eaa44771b80913bdd1304a476b388a4d6be38

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Epidemiology

Børge G. Nordestgaard

In Pathology and Forensic Medicine

Citations in the corpus

Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping (2017, background): “Mutation of this gene predisposes hereditary breast cancer, which also resembles sporadic core basal tumors [33-35].”
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer (2009, neutral): “Age at diagnosis, y ≤ 40 34 (10) 380 (9) 82 (5.4) 82 (9.7) 21 (9.5) 185 40 – 49 73 ( 20 ) 767 (19) 261 (17.1) 175 (20.7) 49 (22.1) 485 50 – 65 119 (33) 1435 (36) 566 (37.0) 275 (32.5) 78 (35.1) 919 >65 124 (35) 1464 (36) 621 (40.6) 314 (37.1) 74 (33.3) 1099 Unknown 7 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0”
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011, background): “17 and (4) lack of expression of ER, PR, and HER2 in conjunction with expression of CK5s6 andsor EGFR”
Triple-negative breast cancer--current status and future directions. (2009, background): “Using the five-marker method described above, patients with BL TNBC had significantly decreased BC-specific OS compared with patients with the remaining non-basal TNBC; among patients treated by adjuvant anthracycline-based chemotherapy, the addition of basal markers allowed for identification of a ”
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011, methodology): “CBP has been used to recapitulate the related “basal-like” breast cancers (1,2) and is associated with short- and long-term prognosis (3).”
Deconstructing the molecular portraits of breast cancer (2010, background): “Furthermore, in a series of 4046 breast tumors (Cheang et al., 2008), 17% (639 of 3744) were defined as the triple-negative, whereas 9.0% were Basal-like by the five-marker Core Basal definition.”
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies (2010, methodology): “reported a significantly poorer survival in CBP tumours compared to the 5NP tumours [10], an observation that supports the notion that the two are biologically distinct types of the TNP tumours.”
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, methodology): “Moreover, evaluation of cytokeratin 5/6 and epidermal growth factor receptor is utilized to identify the Basal-like breast cancer among the TNBC [178].”
An overview of triple-negative breast cancer (2016, background): “EGFR inhibitors: A large proportion of TNBC tumors overexpress EGFR and, although its inhibition is not predictive of response in other tumor types, it is a negative prognostic factor in TNBC [136].”
Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer (2010, background): “An immunohistochemical (IHC) definition of basal-like tumors has been developed based on a triple-negative phenotype (ER, PR and amplified HER-2/Neu negative) and expression of either epidermal growth factor receptor (EGFR) or cytokeratin 5/6 [48, 49].”
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. (2009, background): “In combination with EGFR and cytokeratin 5/6, these markers provide high specificity in identifying basal-like tumors (Cheang et al. 2008).”